Fungal lung disease and respiratory infection
Fungal Foes: The Impact and Treatment of Endemic Mycoses
Endemic mycoses are environmental fungal infections that commonly enter the body through the lungs. Some cause mild, self-limiting illness, while others can produce severe pneumonia, chronic lung disease, meningitis or infection that spreads throughout the body.
- Histoplasmosis
- Cryptococcosis
- Blastomycosis
- Mucormycosis
- Fungal diagnosis
- Antifungal treatment
Environmental exposure matters
Travel, occupation, construction work, caving, farming and contact with soil, bird droppings or bat droppings can provide important diagnostic clues.
Fungal infection can mimic other diseases
Endemic mycoses may resemble bacterial pneumonia, tuberculosis, inflammatory lung disease or lung cancer on symptoms and imaging.
An introduction to endemic mycoses
The lungs are often the first organs affected because spores enter through the respiratory tract. Many infections remain mild or cause no obvious symptoms. Others produce pneumonia, persistent lung abnormalities or infection that spreads beyond the chest.
Disease severity depends on several factors, including:
- the fungal species;
- the intensity of exposure;
- the person’s immune function;
- underlying respiratory or medical conditions;
- how quickly the infection is recognised;
- whether the infection has spread outside the lungs.
Endemic does not mean limited to one country
A fungus may be more common in a defined geographical region, but infection can be diagnosed elsewhere because of travel, migration, occupational exposure and changing environmental conditions.
Epidemiology: where and how exposure occurs
Epidemiology describes how disease is distributed across populations. For fungal infections, geography and environmental exposure can be central to making the correct diagnosis.
Geography
Some fungi are concentrated around river valleys, forested areas, moist soil or defined climatic regions.
Climate
Temperature, humidity and rainfall influence fungal growth and the release of airborne spores.
Environmental disturbance
Excavation, demolition, farming, landscaping and cave exploration can aerosolise spores.
Host susceptibility
Immune suppression, diabetes, transplantation and chronic lung disease can increase the risk of severe illness.
Tell your clinician about travel and exposure
Important exposures may have occurred months or years earlier. Mention previous residence abroad, travel, cave visits, building work, bird or bat exposure, gardening and occupational contact with soil or organic dust.
Histoplasmosis: the hidden threat
Histoplasma capsulatum is associated with soil enriched by bird or bat droppings. It is classically linked with the Ohio and Mississippi River valleys in the United States, although infection occurs in other regions worldwide.
Exposure
Caves, old buildings, chicken coops, demolition sites and disturbed soil may produce significant spore exposure.
Pulmonary symptoms
Fever, cough, chest discomfort, headache, fatigue and breathlessness may resemble a viral illness or pneumonia.
Severe disease
Heavy exposure or impaired immunity can result in severe pulmonary or disseminated infection.
Chronic pulmonary histoplasmosis may occur in people with structural lung disease, particularly emphysema. Imaging can show cavities or abnormalities that resemble tuberculosis or lung cancer.
Cryptococcosis: a global concern
Cryptococcosis is caused primarily by Cryptococcus neoformans and Cryptococcus gattii. These fungi occur in the environment, including soil, decaying wood and material contaminated with bird droppings.
Pulmonary infection
Lung disease may cause cough, chest pain, breathlessness or fever, but some cases are found incidentally on imaging.
Immune suppression
Severe infection is more likely in people with advanced HIV, transplantation or other forms of impaired immunity.
Central nervous system spread
Cryptococcus can spread to the brain and meninges, causing cryptococcal meningitis.
Possible meningitis requires urgent assessment
Headache, confusion, fever, vomiting, light sensitivity, visual disturbance, seizures or marked drowsiness may indicate central nervous system involvement and require urgent medical care.
Blastomycosis: a regional risk
Blastomycosis is caused by fungi in the Blastomyces group. It is particularly associated with parts of North America, including regions around the Great Lakes and the Mississippi and Ohio River basins.
Environmental source
The fungus is linked to moist soil, woodland and decomposing vegetation.
Respiratory disease
Fever, cough, chest pain, sweats, breathlessness and fatigue can resemble bacterial pneumonia.
Spread beyond the lungs
Infection may affect the skin, bones, genitourinary system or central nervous system.
Imaging can resemble lung cancer
Blastomycosis may produce a mass, nodule or area of consolidation. Microbiology and tissue sampling may be needed to distinguish fungal infection from malignancy.
Mucormycosis: a rapidly progressive fungal infection
Pulmonary mucormycosis can occur in people with severe immune suppression, haematological malignancy, transplantation, uncontrolled diabetes or prolonged corticosteroid exposure.
Pulmonary symptoms
Fever, cough, breathlessness, chest pain and coughing up blood may develop.
Tissue invasion
The fungus can invade blood vessels, impair blood supply and cause tissue damage.
Urgent treatment
Rapid diagnosis, antifungal therapy and sometimes surgery are required.
Mucormycosis is a medical emergency
Suspected pulmonary, sinus, orbital or cerebral mucormycosis requires urgent specialist management because progression can be rapid and life-threatening.
Symptoms of fungal lung infection
Symptoms vary according to the fungus, immune status and whether the infection remains confined to the lungs.
Cough
The cough may be dry or productive and can persist despite standard antibiotic treatment.
Fever
Fever may be mild or severe and may occur with sweats, chills and general malaise.
Breathlessness
Breathlessness may result from pneumonia, widespread lung inflammation or underlying respiratory disease.
Chest discomfort
Chest pain may reflect inflammation of the lungs or pleura.
Fatigue and weight loss
Persistent infection can produce marked tiredness, reduced appetite and unintentional weight loss.
Haemoptysis
Some fungal infections can cause blood-stained sputum or more significant bleeding.
Persistent cough can also have many non-infectious causes. Read more about specialist chronic cough assessment .
Diagnosing endemic mycoses
| Infection | Possible tests | Important considerations |
|---|---|---|
| Histoplasmosis | Antigen testing, antibody testing, fungal culture, microscopy and histopathology | Antigen testing may be particularly useful in severe or disseminated disease |
| Cryptococcosis | Cryptococcal antigen, fungal culture, microscopy and cerebrospinal fluid assessment where indicated | Central nervous system involvement must be actively considered |
| Blastomycosis | Fungal culture, microscopy, histopathology, antigen testing and selected molecular tests | Results may overlap with other fungal infections |
| Mucormycosis | Urgent tissue biopsy, histopathology, culture and selected molecular testing | Treatment may begin before culture confirmation when clinical suspicion is high |
Other investigations
Chest imaging
Chest X-ray and CT may show nodules, consolidation, enlarged lymph nodes, cavities, masses or diffuse lung abnormalities.
Respiratory samples
Sputum, bronchoscopy washings or bronchoalveolar lavage can be tested by microscopy, culture, antigen assays and molecular methods.
Tissue biopsy
Histopathology may demonstrate fungal organisms and tissue invasion when less invasive tests are inconclusive.
Immune assessment
HIV testing, immune-cell counts and review of medicines may help identify why severe fungal infection developed.
A negative test does not always exclude fungal infection
Test sensitivity varies according to the organism, sample type, disease location and immune status. Results must be interpreted alongside imaging, exposure history and the overall clinical picture.
Treating endemic fungal infections
Treatment depends on the specific fungus, severity, site of infection, immune status and possible antifungal resistance. Therapy can last for several months or longer.
Histoplasmosis
Itraconazole may be used for selected mild or moderate disease. Severe or disseminated infection may require initial liposomal amphotericin B followed by itraconazole.
Cryptococcosis
Severe disease or meningitis often requires induction treatment with amphotericin B and flucytosine, followed by fluconazole consolidation and maintenance.
Blastomycosis
Itraconazole is commonly used for mild or moderate disease. Severe pulmonary or central nervous system disease may require amphotericin B.
Mucormycosis
Management generally requires urgent liposomal amphotericin B, reversal of underlying risk factors and surgical removal of infected tissue where possible.
Why monitoring matters
Kidney function
Amphotericin formulations can affect kidney function and electrolytes.
Liver function
Azole antifungals can affect the liver and require blood-test monitoring.
Drug interactions
Antifungals can interact with anticoagulants, immunosuppressants, cardiac medicines and many other drugs.
Drug absorption
Acid-suppressing medicines, food and gastrointestinal problems can influence absorption of some antifungal treatments.
Treatment response
Symptoms, inflammatory markers, microbiology and repeat imaging may be used to assess improvement.
Relapse risk
Immunocompromised patients may require longer treatment or suppressive therapy.
Antifungal medicines require specialist prescribing
Antifungal treatment should not be self-started or borrowed. Selection, dose and duration depend on the organism, severity, organ function, other medicines and relevant laboratory results.
Who is at greater risk of severe infection?
Transplant recipients
Anti-rejection medicines reduce immune responses and can allow fungal infection to progress.
Haematological disease
Leukaemia, lymphoma, chemotherapy and prolonged neutropenia can markedly increase risk.
HIV
Advanced immune suppression increases the risk of disseminated histoplasmosis and cryptococcal meningitis.
Corticosteroid treatment
Prolonged or high-dose steroid treatment can impair fungal immune defence.
Diabetes
Poorly controlled diabetes, particularly diabetic ketoacidosis, is strongly associated with mucormycosis.
Chronic lung disease
Emphysema, cavities and other structural lung abnormalities may increase susceptibility to chronic fungal disease.
Can endemic mycoses be prevented?
Complete avoidance is not always possible because fungal spores are naturally present in the environment. Risk can sometimes be reduced, especially for highly immunocompromised people.
Avoid high-risk exposure
Avoid disturbing heavily contaminated soil, bird roosts, bat colonies or enclosed caves when medically vulnerable.
Use workplace controls
Dust suppression, ventilation and appropriate respiratory protection can reduce occupational exposure.
Optimise medical conditions
Good diabetes control and careful management of immune suppression may reduce susceptibility.
Seek advice before travel
Immunocompromised travellers may benefit from advice about high-risk activities and destinations.
Investigate persistent symptoms
Early assessment may prevent prolonged illness and dissemination.
Keep exposure records
Recording travel and occupational exposure can assist future diagnostic assessment.
When should you seek specialist assessment?
Arrange respiratory review when:
- respiratory symptoms persist despite treatment;
- antibiotics have not produced the expected improvement;
- imaging shows unexplained nodules, cavities or masses;
- you have relevant travel or environmental exposure;
- you are immunocompromised;
- fungal infection has been identified in a respiratory sample.
Seek urgent medical help when:
- breathlessness is severe or rapidly worsening;
- you cough up a significant amount of blood;
- you develop confusion, severe headache or seizures;
- oxygen levels are low or falling;
- you are severely immunocompromised and acutely unwell;
- mucormycosis is suspected.
Persistent or unusual infections can be assessed through the London Chest Specialist chest infection diagnosis and treatment service .
Severe fungal disease can be life-threatening
Do not wait for a routine outpatient appointment if there is severe breathing difficulty, significant haemoptysis, collapse, confusion, meningitis symptoms or rapid deterioration.
Frequently asked questions
Are endemic mycoses contagious?
Most are acquired from the environment rather than through routine person-to-person transmission.
Can fungal lung infection look like bacterial pneumonia?
Yes. Fever, cough, consolidation and breathlessness can occur with both. Travel, immune status and targeted testing help distinguish them.
Can endemic mycoses resemble lung cancer?
Yes. Nodules, masses, lymph-node enlargement and cavities may mimic malignancy. Tissue or microbiological confirmation may be needed.
Does everyone exposed to fungal spores become ill?
No. Many exposed people remain asymptomatic or develop mild illness. Severe disease is more likely after intense exposure or in people with impaired immunity.
Can infection appear long after travel?
Yes. Some fungal infections can remain dormant or present later, particularly when immune function changes.
Will ordinary antibiotics treat fungal pneumonia?
No. Antibiotics used for bacterial infection do not treat fungal disease. The correct antifungal depends on the organism and severity.
How long does antifungal treatment last?
Treatment may last several weeks, months or longer. Duration depends on the fungus, infection site, immune status and response.
Is amphotericin B always required?
No. It is generally reserved for severe, disseminated, central nervous system or rapidly progressive disease.
Can fungal infection spread outside the lungs?
Yes. Disseminated infection may involve the brain, skin, bones, adrenal glands, liver, spleen or other organs.
When is bronchoscopy needed?
Bronchoscopy may be useful when sputum is unavailable, infection is severe, imaging is unusual or tissue and lower respiratory samples are required.
Can healthy people develop severe disease?
Yes, although severe infection is less common. Heavy exposure and particular fungal species can cause significant illness in otherwise healthy people.
Should a positive fungal culture always be treated?
Not automatically. Results must be interpreted alongside sample quality, symptoms, imaging and whether the organism represents infection, colonisation or contamination.
Conclusion
Endemic and environmentally acquired fungal infections are important causes of pulmonary and systemic disease. Histoplasmosis, cryptococcosis and blastomycosis commonly begin after environmental spores are inhaled, while mucormycosis primarily threatens people with major underlying risk factors.
These infections can resemble bacterial pneumonia, tuberculosis, inflammatory lung disease or cancer. Accurate diagnosis therefore depends on combining exposure history, imaging, microbiology, antigen testing, molecular methods and tissue examination where appropriate.
Treatment must be tailored to the organism, disease severity, immune status and organs involved. Antifungal drugs can have important toxicities and interactions, making specialist supervision and monitoring essential.
People with persistent respiratory symptoms, unusual imaging, relevant travel or environmental exposure, or impaired immunity should seek timely medical assessment. A respiratory infection specialist can coordinate the necessary investigations and treatment.
Concerned About a Persistent or Unusual Chest Infection?
Specialist respiratory assessment can review your symptoms, travel and exposure history, immune status, chest imaging and microbiology to determine whether fungal or another unusual infection should be investigated.
